NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (en:Method) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (en:Method)
EP (6) EP2277535A3 (en:Method)
JP (4) JP2002539273A (en:Method)
KR (3) KR100798212B1 (en:Method)
CN (3) CN100339130C (en:Method)
AR (3) AR022965A1 (en:Method)
AT (3) ATE387214T1 (en:Method)
AU (3) AU750913B2 (en:Method)
BE (1) BE1025464I2 (en:Method)
BR (4) BR0009166A (en:Method)
CA (3) CA2366152A1 (en:Method)
CY (3) CY1107561T1 (en:Method)
CZ (3) CZ303653B6 (en:Method)
DE (4) DE60043930D1 (en:Method)
DK (2) DK1162999T3 (en:Method)
ES (3) ES2275499T3 (en:Method)
FR (1) FR10C0008I2 (en:Method)
HK (3) HK1043728B (en:Method)
HU (4) HUP0200664A2 (en:Method)
IL (5) IL145044A0 (en:Method)
LU (1) LU91652I2 (en:Method)
MX (1) MXPA01009452A (en:Method)
MY (2) MY125387A (en:Method)
NL (1) NL300415I1 (en:Method)
NO (4) NO20014322L (en:Method)
NZ (3) NZ513841A (en:Method)
PL (3) PL203917B1 (en:Method)
PT (2) PT1162999E (en:Method)
SI (2) SI1163000T1 (en:Method)
TR (3) TR200102739T2 (en:Method)
TW (3) TWI286938B (en:Method)
WO (3) WO2000056358A2 (en:Method)

Families Citing this family (288)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
PL203917B1 (pl) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposĆ³b jej wytwarzania oraz zastosowanie
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EA006947B1 (ru) 2001-01-23 2006-06-30 ŠŠ²ŠµŠ½Ń‚Šøс ŠŸŠ°ŃŃ‚ŠµŃ€ ŠŸŠ¾Š»ŠøŠ²Š°Š»ŠµŠ½Ń‚Š½Š°Ń Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š²Š°Ń ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“Š½Š¾-Š±ŠµŠ»ŠŗŠ¾Š²Š°Ń ŠŗŠ¾Š½ŃŠŃŽŠ³ŠøрŠ¾Š²Š°Š½Š½Š°Ń Š²Š°ŠŗцŠøŠ½Š°
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
WO2003094960A2 (en) * 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 åÆé¾™ęœ‰é™å…¬åø å¹æę³›é˜²å¾”é«˜ęÆ’ę€§č„‘č†œē‚ŽēƒčŒč°±ē³»ēš„å¤šč‚½-ē–«č‹—
AU2003274011B2 (en) * 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
MY145693A (en) 2002-11-01 2012-03-30 Glaxosmithkline Biolog Sa A method of drying without freezing or bubbling
ES2648046T3 (es) 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacĆ”rido para infecciones estafilocĆ³cicas
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5ā€² CpG nucleic acids and methods of use
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT1587537E (pt) * 2003-01-30 2012-05-30 Novartis Ag Vacinas injetĆ”veis contra mĆŗltiplos serogrupos meningocĆ³cicos
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
BRPI0408094A (pt) * 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificaĆ§Ć£o de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarƬdeo capsular-pneumolisina bacteriano, composiĆ§Ć£o imunogĆŖnica, vacina, processo de produĆ§Ć£o da vacina, mĆ©todo de tratamento ou prevenĆ§Ć£o de infecĆ§Ć£o por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarƬdeo-pneumolisina bacteriano
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
CN1798548B (zh) 2003-06-02 2010-05-05 čÆŗ华ē–«č‹—å’ŒčÆŠę–­å…¬åø åŸŗäŗŽå«åø附ē±»ęƒē“ å’Œå«å¤šē³–ęŠ—åŽŸå¾®ē²’体ēš„免ē–«åŽŸę€§ē»„合ē‰©
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2005237289B2 (en) 2004-04-30 2011-08-04 Glaxosmithkline Biologicals S.A. Meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2351772B1 (en) 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
CN101203529A (zh) 2005-02-18 2008-06-18 čÆŗ华ē–«č‹—å’ŒčÆŠę–­å…¬åø ę„č‡Ŗ脑膜ē‚Ž/脓ęƒē—‡ē›øå…³ę€§å¤§č‚ ę†čŒēš„蛋ē™½č“Ø和ę øé…ø
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensƦtning
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
BRPI0612654B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa mƩtodo para conjugar um sacarƭdeo a uma proteƭna, e, conjugado sacarƭdeo-proteƭna
AU2006286228A1 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5215865B2 (ja) 2005-11-22 2013-06-19 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ćƒŽćƒ­ć‚¦ć‚¤ćƒ«ć‚¹ęŠ—åŽŸćŠć‚ˆć³ć‚µćƒć‚¦ć‚¤ćƒ«ć‚¹ęŠ—åŽŸ
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI1962899T1 (sl) * 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
KR101737464B1 (ko) * 2006-01-17 2017-05-18 ģ•„ė„“ė„¤ ķ¬ė„“ģŠ¤ź·øė Œ ģ•„ė²  ķ‘œė©“ ė…øģ¶œėœ ķ—¤ėŖØķ•„ė£ØģŠ¤ ģøķ”Œė£Øģ—”ģž ė‹Øė°±ģ§ˆ ļ¼ˆė‹Øė°±ģ§ˆ ļ¼„ ā€• ļ½ļ¼„ļ¼‰
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
EP3006041B1 (en) * 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
EP2004225B1 (en) 2006-03-22 2012-04-25 Novartis AG Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免ē–«åŽŸēµ„合ē‰©
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AU2007307800C1 (en) * 2006-10-10 2014-03-13 Wyeth Llc Purification of Streptococcus pneumoniae type 3 polysaccharides
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2626662T3 (es) * 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacƔrido capsular de Streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
CN101951949B (zh) 2007-10-19 2013-10-02 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒē–«č‹—制剂
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag PolipĆ©ptidos PUfH meningocĆ³cicos
WO2009114485A2 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
MX351810B (es) 2008-07-21 2017-10-27 Brigham & Womens Hospital Inc Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1, 6 glucosamina.
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
MX2011006077A (es) 2008-12-09 2011-09-01 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cnaā€”B domain antigens in vaccines against gram positive bacteria
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AU2010227219B2 (en) 2009-03-24 2014-02-27 Glaxosmithkline Biologicals S.A. Adjuvanting meningococcal factor H binding protein
CN109248313B (zh) 2009-04-14 2023-01-17 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽå…ē–«ęŽ„ē§ä»„ęŠµå¾”é‡‘é»„č‰²č‘”č„ēƒčŒēš„ē»„合ē‰©
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptĆ­dios hĆ­bridos incluindo sequĆŖncias meningocĆ³cicas de fhbp
WO2011027257A2 (en) * 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptĆ­deos de modificaĆ§Ć£o meningocĆ³cica fhbp"
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2784144C (en) 2009-12-17 2017-07-11 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
NZ600978A (en) 2009-12-22 2014-08-29 Celldex Therapeutics Inc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Ɩzellikleri değiştirilmiş faktƶr h bağlama proteinleri (fhbp) ve bunların kullanım yƶntemi.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn VivƵanyag vegyĆ¼let mukĆ³zus membrĆ”nhoz juttatĆ”sĆ”hoz Ć©s kapcsolĆ³dĆ³ kĆ©szĆ­tmĆ©nyek, eljĆ”rĆ”sok Ć©s rendszerek
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
JP2013532008A (ja) 2010-05-28 2013-08-15 惆惈ćƒŖć‚¹ ć‚Ŗćƒ³ćƒ©ć‚¤ćƒ³ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ åÆ¾č©±å¼ćƒć‚¤ćƒ–ćƒŖćƒƒćƒ‰éžåŒęœŸć‚³ćƒ³ćƒ”ćƒ„ćƒ¼ć‚æćƒ»ć‚²ćƒ¼ćƒ ćƒ»ć‚¤ćƒ³ćƒ•ćƒ©ć‚¹ćƒˆćƒ©ć‚Æćƒćƒ£
CN107080838A (zh) * 2010-06-04 2017-08-22 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø ē–«č‹—制剂
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinaciĆ³n con menores dosis de antĆ­geno y/o adyuvante
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 ķŽ˜ķŠøė„“ ģ  ė‚˜ė””ģ—ė¹„ģ¹˜ ģ•„ķŒŒė¦° ģ‹œź²”ė¼ ģ†Œė„¤ģ“ ė°•ķ…Œė¦¬ģ•„ģ˜ ģ„øķ¬ģ™ø ė‹¤ė‹¹ė„˜, ģ“ė„¼ ģ œģ”°ķ•˜ėŠ” ė°©ė²•, ģ“ė„¼ ķ•Øģœ ķ•œ ė°±ģ‹  ė° ģ•½ģ œ ģ”°ģ„±ė¬¼
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ½“ļ½ļ½’ļ¼ļ¼ļ¼™ļ¼–ęŠ—åŽŸćŠć‚ˆć³ļ½“ļ½ļ½’ļ¼’ļ¼ļ¼’ļ¼‘ęŠ—åŽŸć‚’å«ć‚€ć‚­ćƒ£ćƒŖć‚¢åˆ†å­
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
RU2014127714A (ru) 2011-12-08 2016-01-27 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ Š’ŠŠšŠ¦Š˜ŠŠ ŠŠ ŠžŠ”ŠŠžŠ’Š• Š¢ŠžŠšŠ”Š˜ŠŠžŠ’ Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
MX2014010011A (es) 2012-02-24 2014-09-08 Novartis Ag Proteinas y composiciones de pilus.
CN104519910B (zh) 2012-03-07 2017-05-03 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒęŠ—原ēš„含佐剂制剂
CN104159603A (zh) 2012-03-08 2014-11-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åø¦ęœ‰tlr4ęæ€åŠØ剂ēš„č”åˆē–«č‹—
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠŠ½Ń‚ŠøŠ³ŠµŠ½Ń‹ Šø Š°Š½Ń‚ŠøŠ³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
ES2640320T3 (es) * 2012-10-17 2017-11-02 Glaxosmithkline Biologicals S.A. ComposiciĆ³n inmunogĆ©nica que comprende 1 o mĆ”s conjugados de sacĆ”ridos capsulares de Streptococcus pneumoniae y un componente proteico que comprende proteĆ­na E y/o PilA de Haemophilus influenzae
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
EP2996718B1 (en) 2013-05-15 2020-01-15 The Governors of the University of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN110787290B (zh) 2014-01-21 2024-06-04 č¾‰ē‘žå…¬åø 包含ē¼€åˆčšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
CN105934251A (zh) * 2014-01-21 2016-09-07 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
NZ729206A (en) 2014-07-23 2022-07-01 Childrenā€™S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
PT3244917T (pt) 2015-01-15 2023-05-31 Pfizer ComposiƧƵes imunogĆ©nicas para utilizaĆ§Ć£o em vacinas pneumocĆ³cicas
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
CN107849119A (zh) 2015-07-07 2018-03-27 é˜æč“¹é‡Œę–Æč‚”ä»½å…¬åø ē”ØäŗŽę²»ē–—和预防IgE介åƼēš„ē–¾ē—…ēš„ē–«č‹—
JP6994453B2 (ja) 2015-07-21 2022-01-14 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆåŒ–čŽ¢č†œē³–é”žęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ć€ćć‚Œć‚’å«ć‚€ć‚­ćƒƒćƒˆćŠć‚ˆć³ć“ć‚Œć‚‰ć®ä½æē”Ø
HK1248531A1 (zh) 2015-08-25 2018-10-19 å·“ęƔ唔ā€§é˜æę ¼ę‹‰ę²ƒå°” 免ē–«č°ƒčŠ‚ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
EP3405212B1 (en) 2016-01-19 2020-07-08 Pfizer Inc Cancer vaccines
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
US11191822B2 (en) * 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
CN109862908B (zh) 2016-08-05 2023-05-02 圣čÆŗč²Ā·åø•ę–Æ图尔公åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
MY199342A (en) 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
AU2017339577B2 (en) 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
JP2020530478A (ja) 2017-08-14 2020-10-22 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åæœē­”ć‚’å¼·åŒ–ć™ć‚‹ę–¹ę³•
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
NZ765694A (en) 2017-12-06 2024-03-22 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019152925A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN120535570A (zh) 2018-04-11 2025-08-26 ꁩē‰¹ē½—姆公åø ē”ØäŗŽé¢„é˜²å’Œę²»ē–—ē™Œē—‡ēš„ęŠ—åŽŸč‚½
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
JP2021522213A (ja) 2018-04-18 2021-08-30 ć‚Øć‚¹ć‚±ćƒ¼ 惐悤ć‚Ŗ悵悤ć‚Øćƒ³ć‚¹ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ćƒŖ惟惆惃惉 ć‚¹ćƒˆćƒ¬ćƒ—ćƒˆć‚³ćƒƒć‚«ć‚¹ćƒ»ćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒ‹ć‚ØčŽ¢č†œå¤šē³–é”žåŠć³ćć®å…ē–«åŽŸę€§ęŽ„合体
MX2021000548A (es) 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacƔridos en seco.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
CN113453708B (zh) 2018-12-19 2025-02-21 é»˜ę²™äøœęœ‰é™č“£ä»»å…¬åø 包含č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-蛋ē™½ē¼€åˆē‰©ēš„ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
JP2022543281A (ja) 2019-08-05 2022-10-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4357356A3 (en) 2019-11-15 2024-07-31 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245836A (zh) 2021-02-19 2022-12-01 ē¾Žå•†č³½č«¾č²å·“ę–Æ德公åø 重ēµ„ļ½‚åž‹č…¦č†œē‚ŽēƒčŒē–«č‹—
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
EP4463186A1 (en) 2022-01-13 2024-11-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0449856B1 (en) * 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bƦrer for gruppe A streptococcal vaccine
BR9405957A (pt) 1993-03-23 1995-12-12 Smithkline Beecham Biolog ComposiƧƵes de vacina contendo lipidio A deacilatado 3-0 monofosforil
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemĆørebetƦndelse
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EP0832238A1 (en) 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trƤgerprotein-konjugat und einem trƤgerprotein
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
JP2000511411A (ja) 1996-05-01 2000-09-05 悶 惭惃ć‚Æćƒ•ć‚§ćƒ©ćƒ¼ ćƒ¦ćƒ‹ćƒ“ć‚”ćƒ¼ć‚·ćƒ†ć‚£ ꊗā€•č‚ŗē‚ŽēƒčŒćƒÆć‚Æćƒćƒ³ē”Øć®ć‚³ćƒŖćƒ³ēµåˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗ
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
ATE380867T1 (de) 1997-06-03 2007-12-15 Sanofi Pasteur Ltd Lactoferrinrezeptorgen von moraxella
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
EP1067962B1 (en) 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
JP4689044B2 (ja) * 1998-12-21 2011-05-25 ćƒ”ćƒ‡ć‚£ćƒŸćƒ„ćƒ¼ćƒ³ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ē”Ø恮č‚ŗē‚Žé€£éŽ–ēƒčŒć‚æćƒ³ćƒ‘ć‚Æč³ŖćØ免ē–«åŽŸę–­ē‰‡
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
PL203917B1 (pl) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposĆ³b jej wytwarzania oraz zastosowanie
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
WO2000056359A3 (en) 2001-02-01
CZ303653B6 (cs) 2013-01-30
AR022964A1 (es) 2002-09-04
US9168313B2 (en) 2015-10-27
MY125202A (en) 2006-07-31
NO2011014I2 (no) 2011-08-30
FR10C0008I2 (fr) 2012-10-26
EP1880735A3 (en) 2008-03-12
WO2000056360A3 (en) 2001-01-25
EP1776962A1 (en) 2007-04-25
WO2000056358A3 (en) 2001-01-04
CA2365296A1 (en) 2000-09-28
LU91652I9 (en:Method) 2019-01-03
US20030147922A1 (en) 2003-08-07
EP1162998B1 (en) 2010-03-03
PL355180A1 (en) 2004-04-05
BR0009166A (pt) 2001-12-26
CN1192798C (zh) 2005-03-16
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
HU229968B1 (hu) 2015-03-30
HUP0200664A2 (en) 2002-06-29
JP2011057713A (ja) 2011-03-24
HK1043730A1 (zh) 2002-09-27
NL300415I1 (nl) 2009-12-01
JP4846906B2 (ja) 2011-12-28
CZ20013378A3 (cs) 2002-03-13
EP1163000A2 (en) 2001-12-19
KR20020000549A (ko) 2002-01-05
CY2009014I2 (el) 2010-07-28
DE122009000054I1 (de) 2009-12-31
HUP0200367A2 (en) 2002-05-29
HK1043731A1 (en) 2002-09-27
AU3813600A (en) 2000-10-09
CN1351501A (zh) 2002-05-29
BRPI0009163B8 (pt) 2021-05-25
KR100642044B1 (ko) 2006-11-10
HUS1500040I1 (hu) 2018-05-28
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
PL204890B1 (pl) 2010-02-26
CN1191852C (zh) 2005-03-09
TR200102736T2 (tr) 2002-04-22
JP2002540074A (ja) 2002-11-26
US20060002961A1 (en) 2006-01-05
NO20014322L (no) 2001-11-14
BRPI0009163B1 (pt) 2019-04-09
CY1107561T1 (el) 2013-03-13
CA2366314A1 (en) 2000-09-28
SI1163000T1 (sl) 2008-06-30
EP1162999B1 (en) 2006-11-29
ATE459373T1 (de) 2010-03-15
DE60032120D1 (de) 2007-01-11
FR10C0008I1 (fr) 2010-03-26
DE60038166D1 (de) 2008-04-10
MY125387A (en) 2006-07-31
TWI286938B (en) 2007-09-21
HU228499B1 (en) 2013-03-28
TWI281403B (en) 2007-05-21
NO330736B1 (no) 2011-06-27
US8926985B2 (en) 2015-01-06
JP5551579B2 (ja) 2014-07-16
BR0009163A (pt) 2001-12-26
PL203917B1 (pl) 2009-11-30
US20050031646A1 (en) 2005-02-10
AR022965A1 (es) 2002-09-04
SI1162999T1 (sl) 2007-04-30
IL145044A0 (en) 2002-06-30
CY1107390T1 (el) 2010-07-28
LU91652I2 (fr) 2010-10-13
AU750762B2 (en) 2002-07-25
CZ20013379A3 (cs) 2002-03-13
ES2339737T3 (es) 2010-05-25
CN1391481A (zh) 2003-01-15
NO20014323D0 (no) 2001-09-05
AR022963A1 (es) 2002-09-04
PL355264A1 (en) 2004-04-05
PT1162999E (pt) 2007-02-28
US20110217329A1 (en) 2011-09-08
US20060093626A1 (en) 2006-05-04
EP1163000B1 (en) 2008-02-27
CY2009014I1 (el) 2010-07-28
MXPA01009452A (es) 2002-08-06
ES2300255T3 (es) 2008-06-16
NZ513842A (en) 2004-05-28
IL145043A0 (en) 2002-06-30
AU750788B2 (en) 2002-07-25
JP2002540075A (ja) 2002-11-26
KR20020001785A (ko) 2002-01-09
WO2000056359A2 (en) 2000-09-28
DE60038166T2 (de) 2009-03-12
HK1043728B (en) 2007-06-22
CN1351503A (zh) 2002-05-29
IL145043A (en) 2007-06-17
WO2000056358A2 (en) 2000-09-28
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1162999A2 (en) 2001-12-19
ATE387214T1 (de) 2008-03-15
AU750913B2 (en) 2002-08-01
IL145045A0 (en) 2002-06-30
EP2277535A2 (en) 2011-01-26
DK1163000T3 (da) 2008-04-28
WO2000056360A2 (en) 2000-09-28
CZ301445B6 (cs) 2010-03-03
CA2366314C (en) 2012-01-10
AU3430700A (en) 2000-10-09
TR200102739T2 (tr) 2001-12-21
DE60032120T2 (de) 2007-09-20
NZ513840A (en) 2004-02-27
DE60043930D1 (de) 2010-04-15
TR200102735T2 (tr) 2002-04-22
NZ513841A (en) 2001-09-28
DK1162999T3 (da) 2007-03-26
NO2011014I1 (no) 2011-09-19
US20100119544A1 (en) 2010-05-13
BR0009154A (pt) 2001-12-26
AU3291900A (en) 2000-10-09
TWI235064B (en) 2005-07-01
BE1025464I2 (en:Method) 2019-03-06
ATE346608T1 (de) 2006-12-15
NO330532B1 (no) 2011-05-09
KR20020000785A (ko) 2002-01-05
HK1043728A1 (en) 2002-09-27
KR100798212B1 (ko) 2008-01-24
NO20014325D0 (no) 2001-09-05
IL145044A (en) 2007-03-08
NO20014322D0 (no) 2001-09-05
EP2277535A3 (en) 2011-03-09
EP1162998A2 (en) 2001-12-19
NO20014325L (no) 2001-11-14
PL355178A1 (en) 2004-04-05
HK1043731B (en) 2009-01-23
EP1880735A2 (en) 2008-01-23
JP2002539273A (ja) 2002-11-19
HUP0200373A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
BE2018C020I2 (en:Method)
BE2016C007I2 (en:Method)
BE2015C057I2 (en:Method)
BE2015C018I2 (en:Method)
BE2014C017I2 (en:Method)
BE2013C051I2 (en:Method)
BE2013C020I2 (en:Method)
BE2013C015I2 (en:Method)
BE2013C001I2 (en:Method)
BE2012C036I2 (en:Method)
BE2011C004I2 (en:Method)
BE2008C046I2 (en:Method)
BE1025464I2 (en:Method)
BE2010C011I2 (en:Method)
BE2008C047I2 (en:Method)
BRPI0001672A2 (en:Method)
BRPI0001542A2 (en:Method)
BRPI0012675B8 (en:Method)
BRPI0017522A2 (en:Method)
HU0004772D0 (en:Method)
BRMU7902607U2 (en:Method)
BRPI9917761A2 (en:Method)
BRPI0303609A (en:Method)
FI4323U1 (en:Method)
IN188678B (en:Method)